The copper ionophore disulfiram improves mitochondrial function in various yeast and human cellular models of mitochondrial diseases

The copper ionophore disulfiram (DSF) is commonly used to treat chronic alcoholism and has potential anti-cancer activity. Using a yeast-based screening assay of FDA-approved compounds, DSF was herein identified for its ability to improve oxidative phosphorylation-dependent growth of various yeast models of mitochondrial diseases caused by a wide range of defects in ATP synthase, complexes III and IV, cardiolipin remodeling, maintenance and translation of the mitochondrial genome. This compound also showed beneficial effects in cells derived from patients suffering from Barth or MELAS syndromes, two mitochondrial diseases associated respectively with a lack in cardiolipin remodeling and protein synthesis inside the organelle. We provide evidence that the rescuing activity of DSF results from its ability to transport copper ions across biological membranes. Indeed, other copper ionophores (pyrithione and elesclomol) and supplementation of the growth media with copper ions had also beneficial effects in yeast and human cells with dysfunctional mitochondria. Our data suggest that the copper-dependent rescuing activity in these cells results from a better capacity to assemble cytochrome c oxidase. Altogether, our findings hold promise for the development of new therapeutic strategies for mitochondrial disorders.

Authors

Institutions

Publication Details

Journal
Human Molecular Genetics
Published
2025-04-29
DOI
https://doi.org/10.1093/hmg/ddaf061
Citations
3
Primary Topic
Mitochondrial Function and Pathology
Type
article
Field-Weighted Citation Impact
2.42
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The copper ionophore disulfiram improves mitochondrial function in various yeast and human cellular models of mitochondrial diseases

Véronique Paquis‐Flucklinger, Valérie Desquiret‐Dumas, Nathalie Bonnefoy, Marine Bouhier et al.
3 citations
Human Molecular Genetics
Mitochondrial Function and Pathology
2.42
article

The copper ionophore disulfiram improves mitochondrial function in various yeast and human cellular models of mitochondrial diseases

Véronique Paquis‐Flucklinger, Valérie Desquiret‐Dumas, Nathalie Bonnefoy, Marine Bouhier, Naïg Guéguen, Elodie Sardin, Laetitia Dard, Cristina Panozzo, Aurélie Renaud, Agnès Rötig, Anaïs Hoarau, Claire Almyre, Aurore Inisan, Olivier R. Baris, Gwendal Dujardin, Déborah Tribouillard‐Tanvier, Bénédicte Lelièvre, Nadège Loaëc, Carole H. Sellem, John P. Richard, François Godard, Marc Blondel, Stéphane Azoulay, Agnès Delahodde, Vincent Procaccio, Vanessa Bergeron, Nolwenn Bounaix, Anne-Louise Cayer
article en
3 citations

Abstract

The copper ionophore disulfiram (DSF) is commonly used to treat chronic alcoholism and has potential anti-cancer activity. Using a yeast-based screening assay of FDA-approved compounds, DSF was herein identified for its ability to improve oxidative phosphorylation-dependent growth of various yeast models of mitochondrial diseases caused by a wide range of defects in ATP synthase, complexes III and IV, cardiolipin remodeling, maintenance and translation of the mitochondrial genome. This compound also showed beneficial effects in cells derived from patients suffering from Barth or MELAS syndromes, two mitochondrial diseases associated respectively with a lack in cardiolipin remodeling and protein synthesis inside the organelle. We provide evidence that the rescuing activity of DSF results from its ability to transport copper ions across biological membranes. Indeed, other copper ionophores (pyrithione and elesclomol) and supplementation of the growth media with copper ions had also beneficial effects in yeast and human cells with dysfunctional mitochondria. Our data suggest that the copper-dependent rescuing activity in these cells results from a better capacity to assemble cytochrome c oxidase. Altogether, our findings hold promise for the development of new therapeutic strategies for mitochondrial disorders.

Human Molecular GeneticsVol. 34(12)
Centre National de la Recherche Scientifique (FR), Université de Bordeaux (FR), Inserm (FR), Université Côte d'Azur (FR), Université Paris Cité (FR), Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR), Université Paris-Saclay (FR), Centre Hospitalier Universitaire de Nice (FR), Sorbonne Université (FR), Institut de Chimie de Nice (FR), Institut de Biologie Physico-Chimique (FR), Centre Hospitalier Universitaire d'Angers (FR), Institut de Recherche sur le Cancer et le Vieillissement de Nice (FR), CEA Paris-Saclay (FR), Établissement Français du Sang (FR), Institut de Biochimie et Génétique Cellulaires (FR), Institut des Maladies Génétiques Imagine (FR), Laboratoire de Biologie Moléculaire et Cellulaire des Eucaryotes (FR), Université d'Angers (FR)
Good health and well-being
Openalex Percentile: Top 12%
Mitochondrial Function and Pathology
2.42
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.